AccuNeb is a brand name of albuterol, approved by the FDA in the following formulation(s):
ACCUNEB (albuterol sulfate - solution; inhalation)
Manufacturer: DEY
Approval date: April 30, 2001
Strength(s): EQ 0.021% BASE [RLD][AN], EQ 0.042% BASE [RLD][AN]
Has a generic version of AccuNeb been approved?
A generic version of AccuNeb has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to AccuNeb and have been approved by the FDA:
albuterol sulfate solution; inhalation
Manufacturer: APOTEX INC
Approval date: April 5, 2010
Strength(s): EQ 0.021% BASE [AN], EQ 0.042% BASE [AN]
Manufacturer: NEPHRON
Approval date: June 28, 2004
Strength(s): EQ 0.042% BASE [AN]
Manufacturer: NEPHRON
Approval date: March 31, 2010
Strength(s): EQ 0.021% BASE [AN]
Manufacturer: WATSON LABS
Approval date: September 25, 2007
Strength(s): EQ 0.021% BASE [AN], EQ 0.042% BASE [AN]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of AccuNeb. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
Patent 6,702,997
Issued: March 9, 2004
Inventor(s): Imtiaz; Chaudry & Partha; Banerjee
Assignee(s): Dey, L.P.
The present invention relates to an albuterol inhalation solution, system, kit and method for relieving bronchospasm in children suffering from asthma. In one alternative embodiment, the solution of the present invention is a sterile, premixed, premeasured single unit dose of albuterol for asthmatic patients 2 to 12 years of age. The present solution may be free of anti-microbial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 0.63 mg or about 1.25 mg albuterol.Patent expiration dates:
- December 28, 2021✓
- December 28, 2021
See also...
- AccuNeb Solution Consumer Information (Wolters Kluwer)
- Accuneb Consumer Information (Cerner Multum)
- Accuneb Advanced Consumer Information (Micromedex)
- Albuterol Consumer Information (Drugs.com)
- Albuterol Consumer Information (Wolters Kluwer)
- Albuterol Aerosol Consumer Information (Wolters Kluwer)
- Albuterol Controlled-Release Tablets Consumer Information (Wolters Kluwer)
- Albuterol Extended-Release Tablets Consumer Information (Wolters Kluwer)
- Albuterol Solution Consumer Information (Wolters Kluwer)
- Albuterol Syrup Consumer Information (Wolters Kluwer)
- Albuterol Consumer Information (Cerner Multum)
- Albuterol inhalation Consumer Information (Cerner Multum)
- Alti-Salbutamol Inhalation Aerosol Advanced Consumer Information (Micromedex)
- Apo-Salvent Advanced Consumer Information (Micromedex)
- Apo-Salvent Inhaler Advanced Consumer Information (Micromedex)
- ReliOn Ventolin HFA Advanced Consumer Information (Micromedex)
- Salbutamol Advanced Consumer Information (Micromedex)
- Salbutamol Nebuamp Advanced Consumer Information (Micromedex)
- Salbutamol Respirator Solution Advanced Consumer Information (Micromedex)
- Ventolin Inhaler Advanced Consumer Information (Micromedex)
- Ventolin Nebules P.F. Advanced Consumer Information (Micromedex)
- Ventolin Respirator Advanced Consumer Information (Micromedex)
- Albuterol Advanced Consumer Information (Micromedex)
- Albuterol Inhalation Advanced Consumer Information (Micromedex)
- Albuterol AHFS DI Monographs (ASHP)
No comments:
Post a Comment